EC
ARQT icon

EcoR1 Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

EcoR1 Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-500,000
Closed -$4.96M – 57
2024
Q1 		$4.96M Buy
+500,000
New +$3.73M 0.13% 51
2023
Q2 		– Sell
-415,322
Closed -$4.57M – 55
2023
Q1 		$4.57M Hold
415,322
– – 0.15% 39
2022
Q4 		$6.15M Hold
415,322
– – 0.19% 46
2022
Q3 		$7.94M Sell
415,322
-480,181
-54% -$10.9M 0.23% 39
2022
Q2 		$19.1M Hold
895,503
– – 0.66% 28
2022
Q1 		$17.2M Buy
+895,503
New +$15.1M 0.54% 37

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EcoR1 Capital's ARQT Position: Q2 2024 in Review

EcoR1 Capital sold out of Arcutis Biotherapeutics (ARQT) in Q2 2024, closing a stake of 500,000 shares — an estimated $4.96M sold.

EcoR1 Capital first reported a position in ARQT in Q1 2022 and held it in 6 quarters. The position peaked at $19.1M in Q2 2022. 186 funds tracked by Wall St. Rank hold ARQT as of Q2 2024.

  • EcoR1 Capital reported no remaining Arcutis Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • EcoR1 Capital sold 500,000 Arcutis Biotherapeutics shares in Q2 2024, an estimated $4.96M.
  • EcoR1 Capital first reported a position in Arcutis Biotherapeutics in Q1 2022 and held it in 6 quarters.
  • EcoR1 Capital's Arcutis Biotherapeutics position peaked at $19.1M in Q2 2022.
  • 186 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2024.

Based on EcoR1 Capital's 13F filing for Q2 2024, filed 14 Aug 2024.